By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


Company News
Cellceutix (CTIX) To Expand Its Skin Product Pipeline 3/3/2015 9:42:39 AM
Cellceutix (CTIX) Enthusiastic About Proposed Budget Increase To $1.2 Billion To Fight Drug-Resistance Bacteria 1/28/2015 12:31:43 PM
Cellceutix (CTIX) Plans Clinical Trial In Patients With Ulcerative Proctitis 1/26/2015 11:00:33 AM
Cellceutix (CTIX) Phase 2b Clinical Trial Of Brilacidin Accepted For Oral Presentation At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) 1/22/2015 11:24:32 AM
Cellceutix (CTIX) Reports Spleen Lesion "Disappears" In Patient With Metastatic Stage 4 Ovarian Cancer In Clinical Trial Of Anti-Cancer Drug Kevetrin 1/20/2015 11:21:49 AM
Cellceutix (CTIX) Invites All To Attend Company's Live Webcast Of Presentation At Biotech Showcase 2015 Today At 2:00 PM PT (5:00 PM ET) 1/13/2015 1:22:33 PM
Cellceutix (CTIX) Releases Confidence Interval Statistics Showing Clinical Success Rates For Brilacidin In Treatment Of ABSSSI 1/5/2015 8:59:08 AM
Cellceutix (CTIX) Adds Dr. Daniel Jorgensen As Chief Medical Officer 12/29/2014 10:13:15 AM
Cellceutix (CTIX) Reports Positive Results Of Brilacidin In Microbiological Intent-To-Treat Population In Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information To Be Submitted 12/23/2014 9:37:59 AM
Cellceutix (CTIX): Prurisol™ For Psoriasis -- FDA Agrees That Phase 2 Study May Begin 12/11/2014 8:15:26 AM